EyePoint Pharmaceuticals, Inc. (EYPT)
Largest Insider Buys in Sector
EYPT Stock Price History Chart
EYPT Stock Performance
About EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the …
Insider Activity of EyePoint Pharmaceuticals, Inc.
Over the last 12 months, insiders at EyePoint Pharmaceuticals, Inc. have bought $37.81M and sold $79.51M worth of EyePoint Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at EyePoint Pharmaceuticals, Inc. have bought $22.49M and sold $43.05M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Cormorant Asset Management, LP (10 percent owner) — $639.58M. Zaderej Karen L. (director) — $199,500. ANDO GORAN (director) — $39,750.
The last purchase of 5,000 shares for transaction amount of $39,750 was made by ANDO GORAN (director) on 2024‑08‑21.
List of Insider Buy and Sell Transactions, EyePoint Pharmaceuticals, Inc.
| 2024-08-21 | director | 5,000 0.0082% | $7.95 | $39,750 | -2.27% | |||
| 2024-08-20 | director | 2,567 0.0048% | $7.79 | $19,997 | +14.64% | |||
| 2024-08-19 | director | 12,500 0.0235% | $7.98 | $99,750 | +11.40% | |||
| 2024-08-16 | director | 3,173 0.0057% | $7.88 | $25,003 | 0.00% | |||
| 2024-07-12 | Sale | director | 11,625 0.0274% | $10.06 | $116,995 | 0.00% | ||
| 2024-06-03 | Sale | director | 11,625 0.0233% | $10.30 | $119,705 | -10.12% | ||
| 2024-05-14 | Sale | director | 11,625 0.0227% | $12.65 | $147,045 | -27.76% | ||
| 2024-05-06 | 10 percent owner | 850,000 1.8064% | $11.86 | $10.08M | -19.44% | |||
| 2024-04-18 | 10 percent owner | 581,765 1.2029% | $18.03 | $10.49M | -47.97% | |||
| 2024-02-02 | Sale | SVP & Chief Commercial Officer | 209 0.0007% | $28.49 | $5,954 | -62.53% | ||
| 2024-01-26 | Sale | SVP & Chief Commercial Officer | 26,017 0.0509% | $25.38 | $660,370 | -58.60% | ||
| 2024-01-26 | Sale | Chief Medical Officer | 49,325 0.0975% | $25.66 | $1.27M | -58.60% | ||
| 2024-01-25 | Sale | SVP & Chief Commercial Officer | 600 0.0012% | $25.00 | $15,000 | -55.63% | ||
| 2024-01-25 | Sale | Chief Medical Officer | 600 0.0012% | $25.00 | $15,000 | -55.63% | ||
| 2024-01-24 | Sale | Executive Vice Chair | 29,956 0.0887% | $24.98 | $748,250 | -53.62% | ||
| 2024-01-24 | Sale | SVP & Chief Commercial Officer | 11,300 0.0335% | $25.01 | $282,621 | -53.62% | ||
| 2024-01-24 | Sale | Chief Medical Officer | 11,251 0.0334% | $25.01 | $281,415 | -53.62% | ||
| 2024-01-23 | Sale | Executive Vice Chair | 5,044 0.0144% | $24.97 | $125,950 | -55.33% | ||
| 2024-01-23 | Sale | SVP & Chief Commercial Officer | 900 0.0026% | $25.00 | $22,500 | -55.33% | ||
| 2024-01-23 | Sale | Chief Medical Officer | 5,135 0.0146% | $25.00 | $128,375 | -55.33% |
Insider Historical Profitability
| Cormorant Asset Management, LP | 10 percent owner | 8325000 12.1976% | $7.10 | 6 | 0 | |
| Lurker Nancy | director | 97635 0.1431% | $7.10 | 4 | 4 | <0.0001% |
| Zaderej Karen L. | director | 16500 0.0242% | $7.10 | 1 | 0 | |
| ANDO GORAN | director | 13150 0.0193% | $7.10 | 1 | 0 | |
| DICICCO WENDY F | director | 9967 0.0146% | $7.10 | 1 | 0 |
Institutional Investor Ownership
| Cormorant Asset Management Lp | $142.48M | 13.24 | 6.89M | +14.16% | +$17.67M | 6.64 | |
| Adage Capital Partners Gp L L C | $98.31M | 9.13 | 4.76M | +6.49% | +$5.99M | 0.18 | |
| Suvretta Capital Management, LLC | $77.8M | 7.23 | 3.76M | -7.22% | -$6.06M | 3.29 | |
| Franklin Templeton Investments | $70.06M | 6.51 | 3.39M | -26.97% | -$25.87M | 0.02 | |
| BlackRock | $57.61M | 5.35 | 2.79M | +28.49% | +$12.78M | <0.01 |